Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2026)

Xeris Biopharma Holdings has reported Cash from Financing Activities for 7 years, with the latest figure at -$8.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 181.7% year-over-year to -$8.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.7 million (up 363.01% YoY), and the FY2025 full-year result was $11.4 million, down 68.51% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$8.8 million, down from -$266000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $78.2 million in Q1 2022, with the low at -$8.8 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $9.7 million across 5 years, with a median of $310000.0 in 2022.
• The largest YoY upside for Cash from Financing Activities was 39224.8% in 2022 against a maximum downside of 18800.0% in 2022.
• Xeris Biopharma Holdings' Cash from Financing Activities stood at $49.2 million in 2022, then slumped by 102.51% to -$1.2 million in 2023, then soared by 132.25% to $398000.0 in 2024, then tumbled by 166.83% to -$266000.0 in 2025, then tumbled by 3222.18% to -$8.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$8.8 million (Q1 2026), -$266000.0 (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.